7 results
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
- Pharmacology ... Glucagon-like peptide 1; normally ... Ozempic), or daily tablet ... #Summary #DM2 # ... diabetes #endocrinology
GLP-1 Agonists

Adlyxin (Lixisenatide) Daily
Bydureon (Exenatide ER) Weekly 
Ozempic (Semaglutide) Weekly 
Trulicity (Dulaglutide) Weekly 
Victoza (Liraglutide) Daily
GI tract) and injection ... There is an ORAL ... #Pharmacology #Dosing ... #Diabetes #DM2 ... #Endocrinology
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
4 Inhibitors - Pharmacology ... peptidase 4), which normally ... inactivates GLP ... #Summary #DM2 # ... diabetes #endocrinology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
) - First Oral GLP ... order for the drug ... to remain stable ... semaglutide #Diabetes #Pharmacology ... #Endocrinology
DPP4 Inhibitors - Normal and Renal Dosing

Increase Incretins (GLP-I & GIP) -> Stimulates Insulin, Inhibits Glucagon
DPP4 Inhibitors - Normal ... Increase Incretins (GLP-I ... Renal #Dosing #Pharmacology ... #Management #Diabetes ... #DM2 #Endocrinology
IDSA - Clinical Strategy to Build an Individualized Treatment Regimen for Multi-Drug Resistant Tuberculosis (MDR-TB)
 •
Resistant Tuberculosis ... are contacts of infectious ... MultiDrugResistant #Tuberculosis ... #MDRTB #management ... antimicrobials #regimens #pharmacology
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
Mycobacterium Tuberculosis ... Please refer to the table ... Mycobacterium #Tuberculosis ... Prevention #Treatment #management ... #HIVAIDS #pharmacology